Human epididymis protein 4 inhibits proliferation of human ovarian cancer cells via the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways

International Journal of Gynecological Cancer

Volumn 24, Issue 3, 2014, Pages 427-436

  Kong, Xiuli ^a   Chang, Xiaohong ^a   Cheng, Hongyan ^a   Ma, Rui Qiong ^a   Ye, Xue ^a   Cui, Heng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; Epithelial ovarian cancer; Human epididymis protein 4; Proliferation

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN EPIDIDYMIS PROTEIN 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1; PROTEIN; WFDC2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CELL COUNTING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; CARCINOMA; METABOLISM; OVARY TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84900430419     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000078     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45:350-357.
4. Shridhar V, Lee J, Pandita A, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001;61:5895-5904.
5. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoM.A. Cancer Res. 2003;63:3695-3700.
6. Scholler N, Crawford M, Sato A, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006;12:2117-2124.
7. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315-1319.
8. Montagnana M, Lippi G, Danese E, et al. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer. 2009;101:548.
9. Israeli O, Goldring-Aviram A, Rienstein S, et al. In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet. 2005;160:35-42.
10. Anastasi E, Giovanna Marchei G, Viggiani V, et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010;31:113-119.
11. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
12. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev. 2008;60:261-310.
13. Hayashi H, Tsuchiya Y, Nakayama K, et al. Down-regulation of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling. Genes Cells. 2008;13:941-947.
14. Gan Y, Shi C, Inge L, et al. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 2010;29:4947-4958.
15. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is over-expressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-2169.
16. Yu D, Wolf JK, Scanlon M, et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993;53:891-898.
17. Jurgensmeier JM, Xie Z, Deveraux Q, et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95:4997-5002.
18. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479-489.
19. Murphy KM, Ranganathan V, Farnsworth ML, et al. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ. 2000;7:102-111.
20. Zou S, Cao N, Cheng D, et al. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin. Int J Nanomed. 2012;7:3823-3835.
21. Fan TJ, Han LH, Cong RS, et al. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin. 2005;37:719-727.
22. Jellinger KA. Challenges in neuronal apoptosis. Curr Alzheimer Res. 2006;3:377-391.
23. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Patents Anticancer Drug Discov. 2009;4:28-35.
24. Mercer KE, Pritchard CA. Raf proteins and cancer: B-raf is identified as a mutational target. Biochim Biophys Acta. 2003;1653:25-40.
25. Tanaka Y, Terai Y, Tanabe A, et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther. 2011;11:50-57.
26. Bouchard D, Morisset D, Bourbonnais Y, et al. Proteins with whey-acidic-protein motifs and cancer. lancet Oncol. 2006;7:167-174.
27. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J. 2002;368:233-242.
28. Schalkwijk J, Wiedow O, Hirose S. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J. 1999;340:569-577.
29. Larsen M, Ressler SJ, Lu B, et al. Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J Biol Chem. 1998;273:4574-4584.
30. Westin U, Nystrom M, Ljungcrantz I, et al. The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm. 2002;11:7-12.
31. Alkemade HA, van Vlijmen-Willems IM, van Haelst UJ, et al. Demonstration of skin-derived antileukoproteinase (SKALP) and its target enzyme human leukocyte elastase in squamous cell carcinoM.A. J Pathol. 1994;174:121-129.
32. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847-853.
33. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol. 2004;22:811-819.
34. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768-2773.
35. Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod. 1998;3:86-95.